Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study of Ruxolitinib in Pancreatic Cancer Patients

ClinicalTrials.gov ID: NCT01423604

Public ClinicalTrials.gov record NCT01423604. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 8:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)

Study identification

NCT ID
NCT01423604
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Incyte Corporation
Industry
Enrollment
136 participants

Conditions and interventions

Interventions

  • Capecitabine Drug
  • Placebo Drug
  • Ruxolitinib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2011
Primary completion
May 31, 2013
Completion
Oct 31, 2016
Last update posted
Feb 11, 2018

2011 – 2016

United States locations

U.S. sites
39
U.S. states
26
U.S. cities
39
Facility City State ZIP Site status
Not listed Birmingham Alabama
Not listed Hot Springs Arkansas
Not listed Burbank California
Not listed Los Angeles California
Not listed Santa Monica California
Not listed Denver Colorado
Not listed Stamford Connecticut
Not listed Boynton Beach Florida
Not listed Fort Myers Florida
Not listed St. Petersburg Florida
Not listed Arlington Heights Illinois
Not listed Elks Grove Village Illinois
Not listed Indianapolis Indiana
Not listed Sioux City Iowa
Not listed Lexington Kentucky
Not listed Louisville Kentucky
Not listed Worcester Massachusetts
Not listed Ann Arbor Michigan
Not listed Detroit Michigan
Not listed Grand Rapids Michigan
Not listed Novi Michigan
Not listed Minneapolis Minnesota
Not listed St Louis Missouri
Not listed Voorhees Township New Jersey
Not listed Albuquerque New Mexico
Not listed Lake Success New York
Not listed Durham North Carolina
Not listed Hickory North Carolina
Not listed Canton Ohio
Not listed Dayton Ohio
Not listed Tulsa Oklahoma
Not listed Bend Oregon
Not listed Portland Oregon
Not listed Danville Pennsylvania
Not listed Pittsburgh Pennsylvania
Not listed Knoxville Tennessee
Not listed San Antonio Texas
Not listed Richmond Virginia
Not listed Green Bay Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01423604, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 11, 2018 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01423604 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →